[Exacerbation of psoriasis by treatment with alpha interferon]. 1994

F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián

UI MeSH Term Description Entries
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003230 Conjunctival Neoplasms Tumors or cancer of the CONJUNCTIVA. Conjunctival Neoplasm,Neoplasm, Conjunctival,Neoplasms, Conjunctival
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077190 Interferon alpha-2 Alpha interferon encoded by the human IFNA2 gene. Recombinant forms are used in the treatment of CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; KAPOSI SARCOMA; MELANOMA; and HAIRY CELL LEUKEMIA. IFN-alpha 2,IFN-alpha-2,IFNalpha-2b, Recombinant,Interferon alfa-2a,Interferon alfa-2b,Interferon alpha-2b, Recombinant,Interferon alpha-A,Interferon-alpha 2,Intron A (Interferon),LeIF A,Reaferon,Recombinant Interferon alpha-2a,Recombinant Interferon alpha-2b,Ro 22-8181,Roferon-A,Sch-30500,Viferon,IFNalpha 2b, Recombinant,Interferon alfa 2a,Interferon alfa 2b,Interferon alpha 2,Interferon alpha 2b, Recombinant,Interferon alpha A,Interferon alpha-2a, Recombinant,Recombinant IFNalpha-2b,Recombinant Interferon alpha 2a,Recombinant Interferon alpha 2b,Ro 22 8181,Ro 228181,Roferon A,RoferonA,Sch 30500,Sch30500
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012514 Sarcoma, Kaposi A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. Kaposi Sarcoma,Kaposi's Sarcoma,Multiple Idiopathic Pigmented Hemangiosarcoma,Kaposis Sarcoma,Sarcoma, Kaposi's
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D012878 Skin Neoplasms Tumors or cancer of the SKIN. Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm

Related Publications

F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
January 1990, Dermatologica,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
March 2016, Cutaneous and ocular toxicology,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
January 1989, Deutsche medizinische Wochenschrift (1946),
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
October 1993, Acta dermato-venereologica,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
June 2000, Clinical and experimental dermatology,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
October 1993, The American journal of gastroenterology,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
September 1997, Recenti progressi in medicina,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
January 1987, Dermatologica,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
November 1991, The British journal of dermatology,
F Revenga Arranz, and E Castaño Suárez, and F Vanaclocha Sebastián
December 1996, Journal of the neurological sciences,
Copied contents to your clipboard!